Detection of gelatinase B activity in serum of gastric cancer patients

Table 1 Proteolytic activity and inhibition of metalloproteinase activity in serum of patients with gastric cancer

Sample	BAPNA(mU)	EDTA (mU)	Inhibition in presence of EDTA (%)	1,10-Phen(mU)	Inhibition in presence of 1,10-phen (%)	TNMstage
1	8.6	1.4	83.7	0.9	89.5	–
21	3.1	1.7	45.2	1.6	51.6	II
31	9.0	2.3	74.4	1.7	81.1	IV
41	4.0	2.8	30.0	4.2	–	III
51	8.8	0.0	100.0	2.2	75.0	IV
6	4.5	5.2	–	1.4	68.9	–
7	0.7	2.1	–	3.5	–	–
8	4.9	5.3	–	8.0	–	–
91	7.0	3.3	52.9	5.7	18.6	III
10	6.2	0.0	100.0	3.8	38.7	–
111	2.8	5.6	–	4.2	–	II
121	1.7	1.5	11.8	6.1	–	II
13	6.9	0.6	91.3	0.7	89.9	–
14	8.0	0.3	96.2	1.9	76.2	–
151	5.2	0.1	98.1	1.5	71.2	III
161	1.8	0.7	61.1	2.5	–	I
17	0.8	0.7	12.5	2.3	–	–
18	8.8	1.1	87.5	5.0	43.2	–
191	4.7	1.9	59.6	3.6	23.4	III
201	4.8	1.5	68.8	1.9	60.4	III
21	5.3	0.0	100.0	2.4	54.7	–
22	4.1	0.6	88.7	2.4	41.7	–
231	1.3	0.5	61.5	1.1	15.4	I

¹Radical surgery.

Table 2 Proteolytic activity and inhibition of metalloproteinase activity in serum of control group

Control	BAPNA(mU)	EDTA (mU)	Inhibition in presence of EDTA (%)	1,10-Phen(mU)	Inhibition in presence of EDTA (%)
1	1.3	4.3	-	0.4	69.2
2	0.7	3.2	-	4.3	-
3	0.4	2.3	-	1.7	-
4	4.4	6.8	-	0.9	79.5
5	0.3	1.3	-	1.7	-
6	2.2	0.9	59.1	-	-
7	0.9	1.6	-	2.5	-
8	1.0	0.0	100.0	3.2	-
9	0.3	0.9	-	2.6	-
10	0.3	1.1	-	2.7	-
11	1.7	0.0	100.0	0.0	100.0